Doubts grow as Lilly awaits FDA decision on prasugrel

The FDA on Thursday is scheduled to hand down its decision on prasugrel, an anti-clotting treatment from Eli Lilly and Co. and Daiichi Sankyo Co., but analysts and physicians are expecting a delay and expressed uncertainty about the drug's prospects even if it gets marketing clearance. "I think the data is compelling and prasugrel will be approved, but with a fairly narrow indication," a cardiovascular expert said. A spokeswoman for Lilly refused to comment ahead of the FDA ruling.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Meridian Health Plan
Detroit, MI